RefluxStop® Generates Buzz at the European Foregut Society Meeting
Implantica AG, a pioneering medtech company, has made headlines with its innovative device, RefluxStop®, designed to tackle acid reflux, which affects over a billion individuals worldwide. The recent European Foregut Society (EFS) Annual Meeting showcased this revolutionary product, highlighting its potential impact in treating gastroesophageal reflux disease (GERD).
The EFS meeting gathered renowned surgeons, gastroenterologists, and researchers from across Europe, creating a vibrant environment for discussion and knowledge sharing. The excitement around RefluxStop® was unmistakable, as attendees learned about its groundbreaking results aimed at addressing the fundamental causes of GERD.
The RefluxStop Symposium, entitled 'RefluxStop for GERD: Excellent long-term outcomes', attracted a large audience of approximately 100 healthcare professionals keen to hear the latest findings on the device's effectiveness. A panel of leading experts, including Prof. Sebastian Schoppmann and Dr. med. Yves Borbély, facilitated insights into the successful outcomes generated by RefluxStop® and engaged in meaningful discussions with fellow attendees.
Dr. Peter Forsell, the CEO and founder of Implantica and inventor of RefluxStop®, expressed gratitude to the panelists for providing valuable independent clinical data. He noted that more than 1,400 patients have undergone the RefluxStop® procedure across over 50 leading reflux centers in Europe, with many more waiting to be treated. Dr. Forsell emphasized how the medical community has embraced this innovative solution, illustrating its growing acceptance among top surgeons globally.
Dr. Forsell highlighted the challenges faced by patients suffering from GERD, particularly those who do not respond well to conventional medications. He believes that RefluxStop® offers an essential surgical alternative for these patients, significantly shifting the paradigm in GERD treatment. The ongoing FDA approval process raises hopes for offering this treatment option to patients in the United States soon.
Connect with Implantica
For more details on RefluxStop® and its advancements in treatment, reach out to Nicole Pehrsson, Chief Corporate Affairs Officer, at +41 (0)79 335 09 49.
Implantica is dedicated to enhancing the lives of patients with cutting-edge technology. The company's flagship product, RefluxStop®, is CE-marked and among its many innovations aimed at transforming medical treatments. As a company listed on Nasdaq First North Premier Growth Market, its growth and commitment to medical breakthroughs are evident.
Implantica's focus on an integrated eHealth approach aims to combine technology with healthcare, offering tools designed for patient monitoring and communication from within the body. The future of reflux treatment appears promising as the company continues to advance its product pipeline, which is backed by solid clinical results.
RefluxStop® introduces a notable disruptiveness to traditional surgical solutions. Unlike conventional methods that encircle the esophagus, the RefluxStop® device focuses on restoring physiological functions without compromising the food passage. This innovative approach preserves the body's natural capabilities and encourages it to address the underlying reflux issue.
By reconstructing the essential components of the anti-reflux barrier, RefluxStop® provides long-term relief to patients. It signifies a fresh way to approach gastroesophageal reflux disease, making strides towards improved patient outcomes.
Frequently Asked Questions
What is RefluxStop®?
RefluxStop® is a groundbreaking device designed to treat gastroesophageal reflux disease (GERD) without using conventional surgical methods that may have undesirable side effects.
How does RefluxStop® differ from traditional treatments?
Unlike traditional surgery, which might encircle the esophagus, RefluxStop® maintains the natural position of the lower esophageal sphincter to treat acid reflux more effectively.
What were the highlights of the European Foregut Society Meeting?
The meeting featured discussions on the successful implementation and positive long-term outcomes associated with RefluxStop®, gaining significant attention and enthusiasm from medical professionals.
What is the vision for RefluxStop® in the U.S. market?
Dr. Forsell envisions RefluxStop® becoming a widely accepted treatment option for GERD patients in the U.S. following the completion of the FDA approval process.
How many patients have been treated with RefluxStop® so far?
Over 1,400 patients have undergone the RefluxStop® procedure, showcasing its growing acceptance among healthcare providers in Europe.
